NxStage clears US hurdle in Medisystems acquisition:
This article was originally published in Clinica
US antitrust authorities have completed a review of NxStage Medical's proposed buyout of its long-term business partner Medisystems Corporation, bringing NxStage closer to purchasing the developer of disposables used in dialysis and blood treatment. The firm says it has begun to implement organisational changes in anticipation of the transaction, expected to close during the fourth quarter of 2007. Lawrence, Massachusetts-based NxStage has promoted that Michael Webb to the newly-created position of senior vice-president of quality, regulatory and clinical affairs, whereas, upon the closing of the deal, Phil Licari will resign as senior vice-president and chief operating officer to pursue other opportunities. The deal, signed in June, is valued at around $78.7m (see Clinica No 1259, p 18).
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.